These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34390762)

  • 1. Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: A prospective study.
    Ohara M; Nagaike H; Fujikawa T; Kohata Y; Ogawa M; Omachi T; Sasajima R; Chiba H; Ara T; Sugawara A; Hiromura M; Terasaki M; Mori Y; Fukui T; Hirano T; Yokoyama H; Yamagishi SI
    Diabetes Res Clin Pract; 2021 Sep; 179():108999. PubMed ID: 34390762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Goldenberg R; Gantz I; Andryuk PJ; O'Neill EA; Kaufman KD; Lai E; Wang YN; Suryawanshi S; Engel SS
    Diabetes Obes Metab; 2017 Mar; 19(3):394-400. PubMed ID: 28093853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
    Addy C; Tatosian D; Glasgow XS; Gendrano IN; Kauh E; Martucci A; Johnson-Levonas AO; Selverian D; Matthews CZ; Gutierrez M; Wagner JA; Aubrey Stoch S
    Clin Ther; 2016 Mar; 38(3):516-30. PubMed ID: 26869191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes.
    Sheu WH; Gantz I; Chen M; Suryawanshi S; Mirza A; Goldstein BJ; Kaufman KD; Engel SS
    Diabetes Care; 2015 Nov; 38(11):2106-14. PubMed ID: 26310692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds.
    Gantz I; Sokolova L; Jain L; Iredale C; O'Neill EA; Wei Z; Lam R; Suryawanshi S; Kaufman KD; Engel SS; Lai E
    Clin Ther; 2017 Oct; 39(10):2024-2037. PubMed ID: 28923291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: A systemic review and meta-analysis.
    Wang X; Li X; Qie S; Zheng Y; Liu Y; Liu G
    Medicine (Baltimore); 2018 Aug; 97(34):e11946. PubMed ID: 30142816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omarigliptin for the treatment of type 2 diabetes.
    Tan X
    Endocrine; 2016 Oct; 54(1):24-31. PubMed ID: 27372109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
    Stoimenis D; Karagiannis T; Katsoula A; Athanasiadou E; Kazakos K; Bekiari E; Matthews DR; Tsapas A
    Expert Opin Pharmacother; 2017 Jun; 18(9):843-851. PubMed ID: 28448177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.
    Gantz I; Chen M; Suryawanshi S; Ntabadde C; Shah S; O'Neill EA; Engel SS; Kaufman KD; Lai E
    Cardiovasc Diabetol; 2017 Sep; 16(1):112. PubMed ID: 28893244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes.
    Home P; Shankar RR; Gantz I; Iredale C; O'Neill EA; Jain L; Pong A; Suryawanshi S; Engel SS; Kaufman KD; Lai E
    Diabetes Res Clin Pract; 2018 Apr; 138():253-261. PubMed ID: 29079379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.
    Lee SH; Gantz I; Round E; Latham M; O'Neill EA; Ceesay P; Suryawanshi S; Kaufman KD; Engel SS; Lai E
    BMC Endocr Disord; 2017 Nov; 17(1):70. PubMed ID: 29110647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin.
    Jain L; Chain ASY; Tatosian DA; Hing J; Passarell JA; Kauh EA; Lai E
    Br J Clin Pharmacol; 2019 Dec; 85(12):2759-2771. PubMed ID: 31454094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omarigliptin for the treatment of type 2 diabetes mellitus.
    Evans PM; Bain SC
    Expert Opin Pharmacother; 2016 Oct; 17(14):1947-52. PubMed ID: 27466703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
    Kamrul-Hasan ABM; Alam MS; Talukder SK; Dutta D; Selim S
    Endocrinol Metab (Seoul); 2024 Feb; 39(1):109-126. PubMed ID: 38417828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment.
    Chacra A; Gantz I; Mendizabal G; Durlach L; O'Neill EA; Zimmer Z; Suryawanshi S; Engel SS; Lai E
    Int J Clin Pract; 2017 Jun; 71(6):. PubMed ID: 28449320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Shankar RR; Inzucchi SE; Scarabello V; Gantz I; Kaufman KD; Lai E; Ceesay P; Suryawanshi S; Engel SS
    Curr Med Res Opin; 2017 Oct; 33(10):1853-1860. PubMed ID: 28547998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Handelsman Y; Lauring B; Gantz I; Iredale C; O'Neill EA; Wei Z; Suryawanshi S; Kaufman KD; Engel SS; Lai E
    Curr Med Res Opin; 2017 Oct; 33(10):1861-1868. PubMed ID: 28548024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men.
    Tsuchiya S; Friedman E; Addy C; Wakana A; Tatosian D; Matsumoto Y; Suzuki H; Kauh E
    J Diabetes Investig; 2017 Jan; 8(1):84-92. PubMed ID: 27182005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Patient Satisfaction of the Weekly DPP-4 Inhibitors Trelagliptin and Omarigliptin in 80 Japanese Patients with Type 2 Diabetes.
    Tosaki T; Kamiya H; Yamamoto Y; Himeno T; Kato Y; Kondo M; Yamada Y; Inagaki A; Tsubonaka K; Oshiro C; Katayama T; Hayasaki T; Nakaya Y; Fujiyoshi H; Nakamura J
    Intern Med; 2017 Oct; 56(19):2563-2569. PubMed ID: 28883229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omarigliptin: first global approval.
    Burness CB
    Drugs; 2015 Nov; 75(16):1947-52. PubMed ID: 26507988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.